Literature DB >> 4168056

Production of lymphocytosis by polysaccharide polysulphates (heparinoids).

S Sasaki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4168056     DOI: 10.1038/2141041a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  7 in total

1.  Heparin affects the induction of regulatory T cells independent of anti-coagulant activity and suppresses allogeneic immune responses.

Authors:  Y Kashiwakura; H Kojima; Y Kanno; M Hashiguchi; T Kobata
Journal:  Clin Exp Immunol       Date:  2020-07-15       Impact factor: 4.330

2.  Heparin attenuates low-dose streptozotocin-induced immune diabetes in mice and inhibits the beta-cell binding of T-splenocytes in vitro.

Authors:  P Saï; S Pogu; M Ouary
Journal:  Diabetologia       Date:  1991-04       Impact factor: 10.122

3.  Heparin-induced leukocytosis requires 6-O-sulfation and is caused by blockade of selectin- and CXCL12 protein-mediated leukocyte trafficking in mice.

Authors:  Siyuan Zhang; Eduard Condac; Hong Qiu; Junlin Jiang; Gerardo Gutierrez-Sanchez; Carl Bergmann; Tracy Handel; Lianchun Wang
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

4.  Effect of heparin on antigen-induced airway responses and pulmonary leukocyte accumulation in neonatally immunized rabbits.

Authors:  J M Preuss; C P Page
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

5.  Lymphocytosis induced by polymethacrylic acid. Dose-effect and toxicity.

Authors:  S Ormai; M Palkovits
Journal:  Blut       Date:  1975-10

6.  Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.

Authors:  Lianchun Wang; Jillian R Brown; Ajit Varki; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

7.  Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins.

Authors:  O Lider; E Baharav; Y A Mekori; T Miller; Y Naparstek; I Vlodavsky; I R Cohen
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.